KURA
Kura Oncology, Inc.
$10.86
-0.03 (-0.28%)
At close · Jul 17
Market Cap
$964.09M
Shares
88,774,365
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$67.48M
+25.2%
FY2025
Net Income
-$278.67M
-60.2%
FY2025
Operating Margin
-449.94%
-91.4pp
FY2025
Diluted EPS
-$3.18
-57.4%
FY2025
Operating Cash Flow
-$64.06M
-147.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $71.64M | $67.48M | $53.88M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $260.36M | $251.07M | $169.97M | $115.24M | $92.81M | $84.72M | $60.4M | $47.83M | $46.79M | $26.43M | — | — | — | — | — | — | — | — | — | — | |
| $104.91M | — | $77.11M | $50.57M | $47.05M | $46.54M | $31.5M | $19.65M | $16.1M | $9.65M | — | — | $165.05K | $22.73K | $22.34K | $23.44K | $20.51K | — | — | — | |
| — | $119.98M | $77.11M | $50.57M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $371.11M | $247.08M | $165.8M | $139.87M | $131.26M | $91.9M | $67.48M | $62.88M | $36.08M | $28.37M | $23.87M | — | — | — | — | — | — | — | — | |
| -$317.75M | -$303.63M | -$193.2M | -$165.8M | -$139.87M | — | — | — | — | — | — | — | -$180.69K | -$22.73K | -$22.34K | -$23.44K | -$20.51K | — | — | — | |
| — | -449.94% | -358.55% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $1.47M | $1.51M | $1.62M | $1.55M | $229K | $414K | $578K | $580K | $970K | $888K | $577K | $42K | $24K | $5877 | $4974 | $3600 | $1886 | — | — | — | |
| $1.07M | — | — | — | — | — | — | — | — | $751K | $499K | $128K | — | — | — | — | — | — | — | — | |
| $23.26M | $25.26M | $21.23M | $13.17M | $4.03M | $792K | $2.27M | $4.34M | $2.44M | $643K | $807K | $1.24M | — | — | — | — | — | — | — | — | |
| -$294.49M | -$278.37M | -$171.97M | -$152.63M | -$135.84M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $297K | $2.02M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | |
| -$294.57M | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -$130.47M | -$89.63M | -$63.14M | -$60.45M | -$35.43M | -$27.56M | -$22.63M | -$204.69K | -$28.61K | -$27.32K | -$27.04K | -$22.4K | -$20K | -$33.62K | -$14.98K | |
| — | -412.95% | -322.89% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$295.92M | -$278.41M | -$171.95M | -$145.87M | -$142.08M | -$132.3M | -$89.91M | -$62.68M | -$60.53M | -$35.47M | -$27.49M | -$22.71M | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$3.18 | -$2.02 | -$2.08 | -$2.03 | -$1.97 | -$1.69 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.7M | 9.93M | 4.95M | 5M | 5M | 5M | — | — | — | — |
| shares | — | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.7M | 9.93M | 4.95M | 5M | 5M | 5M | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
—
Biotechnology median 7.37×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration Revenue | $65,350,000 | $53,883,000 | — |
| License and Collaboration Revenue | $65,350,000 | $53,883,000 | $0 |
| Product | $2,132,000 | $0 | $0 |
Key facts
CIK
1422143
CUSIP
50127T109
13F (30d)
20 filings
20 filers
Visit website
Investor relations